Understanding the Body's NATURAL BALANCING SYSTEM
The endocannabinoid system (ECS) is the body’s largest receptor network—an internal balancing system that helps regulate inflammation, metabolism, immune response, pain, mood, and reproduction.
But in today’s world of chronic stress, ultra-processed foods, and sedentary living, that balance is under threat. The ECS plays a vital role in helping the body adapt to this biological mismatch—yet it remains one of the most underexplored systems in modern medicine.
Discovered in the 1990s, Harvard Medical School calls the ECS “essential and mysterious,” with mounting evidence that it plays a role in nearly every physiological system in the body.
At Nalu Bio, we’re addressing what experts have called the “glaring omission” of the ECS from mainstream medicine. Our proprietary, AI-powered platform is designed to close that gap—combining machine learning, and biological modeling to accelerate the development of targeted, non-additive therapeutics.
The ECS is made up of:
For centuries, people have turned to cannabinoids for relief. But natural cannabinoids are inconsistent, poorly absorbed, and often intoxicating–making them unreliable as therapeutic agents.
At Nalu Bio, we’re reengineering what cannabinoids can do—using modern science to deliver consistent, safe, and efficacious therapeutics.
Our AI-powered ECS platform systematically designs novel, non-addictive compounds engineered for precision, safety, efficacy and bioavailability. CB1 and CB2—the ECS’s primary receptors—are part of the GPCR family that underpins 30–40% of all approved drugs. Yet ECS-targeted therapies remain rare, held back by decades of stigma and underinvestment, despite mounting real-world and clinical evidence.
By harnessing the therapeutic potential of these receptors, Nalu Bio is mirroring the success of the GLP-1 market with a platform-driven strategy to deliver a robust ECS Pipeline of prescription therapeutics. And with the FDA’s botanical drug pathway validating the safety profile of cannabinoids, the regulatory environment is increasingly aligned with accelerating ECS innovation into mainstream medicine.
Why Nalu Bio Is Targeting the ECS
Women’s Unique ECS Advantage
Women may be especially well-suited to benefit from ECS-based treatments.
Here’s why:
Notably, the first endocannabinoid discovered—anandamide—was found in the human ovary. Its levels fluctuate with estrogen, highlighting the ECS’s deep connection to reproductive health.
These biological insights allow Nalu Bio to develop targeted, non-hormonal solutions for conditions that have long been underserved by traditional medicine.